



SNO Digest

Weekly news from
the Society for Neuro-Oncology


President Biden Relaunches Cancer Moonshot Program

On February 7, 2022, President Biden relaunched his Cancer Moonshot initiative in order to “end cancer as we know it.” Cancer Moonshot, which President Biden originally launched as Vice President in 2016 after his son Beau Biden died in 2015 of glioblastoma, has ambitious goals including:

- Over the next 25 years, Cancer Moonshot will cut today’s age-adjusted death rate from cancer by at least 50%.
- Improve the experience of people and their families living with and surviving cancer.

Cancer Moonshot is President Biden’s first attempt as President to tackle curing cancer, which was one of his signature issues on the campaign trail. In order to help accomplish his Cancer Moonshot goals, President Biden also pressed Congress to fund the Advanced Research Project Agency for Health (ARPA-H), which he hopes will be housed within the National Institutes of Health. ARPA-H funding has already been included in appropriations legislation in Congress. However, the program will not be established until Congress passes the FY2022 appropriations package. View the White House Press Release on Cancer Moonshot [here](#).

Upcoming and On-Demand Webinars



The Pediatric Special Interest Track is pleased to present the next broadcast of the Pediatric Tumor Board Series. The broadcast entitled Embryonal tumor with multilayered rosettes (ETMR): Evidence-based recommendations for the diagnosis and treatment of this biologically and clinically heterogeneous pediatric CNS tumor will occur live on March 22, 2022, 10:00-11:30 am ET. [Click here to register.](#)



If you did not have the opportunity to catch the webinar, "The Neural Regulation of Cancer," jointly sponsored by the World Federation of Neurology and the Society of Neuro-Oncology, it is available on-demand [here](#).

Educational Programming

[Clinical trial accrual for women and minorities in neuro-oncology.](#)


Dr. Rachna Malani interviews Dr. Hervey-Jumper about his and his team's recent manuscript entitled "A population study of clinical trial accrual for

Neuro-Oncology

The PODCAST

women and minorities in neuro-oncology following the NIH revitalization act", published online in Neuro-Oncology in January 2022. [Listen to the podcast.](#)

From The Journals



The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications

Infiltrative astrocytic tumors with and without isocitrate dehydrogenase (IDH) mutation frequently contain mutations in the TP53 tumor suppressor gene. Disruption of normal p53 protein activity confers neoplastic cells with a number of oncogenic properties and is a common feature of aggressive malignancies. However, the high prevalence of TP53 mutation and its pathogenic role in IDH-mutant (IDHmut) astrocytoma is not well understood. [Click to read the full article.](#)

SNO Career Center



This Week's Featured Listing

The Allegheny Health Network (AHN) is recruiting full-time Neuro Oncology physicians to join their expanding team in Pittsburgh, PA!

[Click here to apply or see other postings!](#)

Upcoming SNO and SNO Affiliated Events



2022 SNO Annual Meeting and Education Day

November 16-20, 2022
Tampa Bay Convention Center



12 - 15 June 2022 in Hamburg

& SIOPE-BTG Meeting 11 - 12 June 2022

www.ispno2022.de

2022 SNO Annual Meeting and Education Day - Call for Abstracts

Abstract deadline - June 1, 2022

For information on the submission categories and requirements, please [click here.](#)

To submit an abstract, please [click here.](#)

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)

June 12-15, 2022, in Hamburg


[Register Here](#)

For information about travel grants for LMIC countries, please [click here.](#)



4th Annual Introduction to Clinical Trial Design and Protocol Development Workshop

Thursday, August 11, 2022
Toronto, Canada



2nd Annual Conference on CNS Clinical Trials and Brain Metastases

An interactive, interdisciplinary conference on primary and metastatic CNS malignancies
August 12-13, 2022 Toronto, Canada

SNO

ASCO

2022 SNO Introduction to Clinical Trial Design and Protocol Development Workshop

August 11, 2022

Application deadline - April 15, 2022

[Apply Here](#)

2nd Annual Conference on Clinical Trials and Brain Metastases

August 12-13, 2022

Call for Abstracts - Deadline: April 18, 2022

[Submit Your Abstract](#)

SNO Membership

The Society for Neuro-Oncology represents over 2,800 professionals dedicated to promoting advances in neuro-oncology through research and education. As part of this commitment, SNO is pleased to introduce a **new category of membership for Allied Health Professionals**. This category of memberships is designed for non-physician clinical health care professionals, including, advance practice professionals, nurses, physician assistants, pharmacists, and others who spend most of their professional activity on the treatment and care of patients with brain and CNS tumors. [Click here for more information.](#) **Now is the time to renew your membership or join the Society.** Click [here](#) today to get started.

SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.



27th Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022

Society for Neuro-Oncology | [Website](#)
[Subscribe to the SNO Digest](#)



Society for Neuro-Oncology | PO 273296, Houston, TX 77277

[Unsubscribe](#) megan@soc-neuro-onc.org

[Update Profile](#) | [About Constant Contact](#)

Sent by snodigest@soc-neuro-onc.org in collaboration with



Try email marketing for free today!